From the screening of 107 RRMS patients, there were 72 total screen failures; 25 responded to high‐dose steroid therapy, while the remaining 47 did not respond to high‐dose steroid therapy, but failed screening due to other criteria such as laboratory abnormalities (ie, HbA1c elevation, anemia, or aspartate aminotransferase/alanine aminotransferase elevation poststeroids). The gene discussed is GPT; the disease is anemia.